×




Pharmacyclics: Financing Research & Development Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Pharmacyclics: Financing Research & Development case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Pharmacyclics: Financing Research & Development case study is a Harvard Business School (HBR) case study written by Richard S. Ruback, Malcolm P. Baker, Aldo Sesia. The Pharmacyclics: Financing Research & Development (referred as “Pharmacyclics Drug” from here on) case study provides evaluation & decision scenario in field of Finance & Accounting. It also touches upon business topics such as - Value proposition, Decision making, Entrepreneurship, Financial analysis, Financial management, Marketing, Research & development.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Pharmacyclics: Financing Research & Development Case Study


Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more cash than ever before, but projections of R&D and marketing expenses were also unprecedented. PCYC's most promising oncology drug, a radiation enhancer called Xcytrin, was in Phase III clinical trials--the rigorous final phase before FDA approval for commercialization. Analysts gave the drug a slightly better than 50% chance of success. This case focuses on stage financing and a simple decision-tree evaluation. Students have the opportunity to consider the impact of past staged financing decisions on the ownership structure of the firm and to evaluate the current stock market price in light of analyst forecasts of the cash flow and the probability of success for each drug. These two analyses help inform the private placement decision.


Case Authors : Richard S. Ruback, Malcolm P. Baker, Aldo Sesia

Topic : Finance & Accounting

Related Areas : Decision making, Entrepreneurship, Financial analysis, Financial management, Marketing, Research & development




Calculating Net Present Value (NPV) at 6% for Pharmacyclics: Financing Research & Development Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10011947) -10011947 - -
Year 1 3447961 -6563986 3447961 0.9434 3252793
Year 2 3970665 -2593321 7418626 0.89 3533878
Year 3 3942755 1349434 11361381 0.8396 3310413
Year 4 3229293 4578727 14590674 0.7921 2557903
TOTAL 14590674 12654987




The Net Present Value at 6% discount rate is 2643040

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Net Present Value
2. Internal Rate of Return
3. Profitability Index
4. Payback Period

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Pharmacyclics Drug have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Pharmacyclics Drug shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of Pharmacyclics: Financing Research & Development

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Finance & Accounting Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Pharmacyclics Drug often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Pharmacyclics Drug needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10011947) -10011947 - -
Year 1 3447961 -6563986 3447961 0.8696 2998227
Year 2 3970665 -2593321 7418626 0.7561 3002393
Year 3 3942755 1349434 11361381 0.6575 2592425
Year 4 3229293 4578727 14590674 0.5718 1846359
TOTAL 10439404


The Net NPV after 4 years is 427457

(10439404 - 10011947 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10011947) -10011947 - -
Year 1 3447961 -6563986 3447961 0.8333 2873301
Year 2 3970665 -2593321 7418626 0.6944 2757406
Year 3 3942755 1349434 11361381 0.5787 2281687
Year 4 3229293 4578727 14590674 0.4823 1557337
TOTAL 9469731


The Net NPV after 4 years is -542216

At 20% discount rate the NPV is negative (9469731 - 10011947 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Pharmacyclics Drug to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Pharmacyclics Drug has a NPV value higher than Zero then finance managers at Pharmacyclics Drug can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Pharmacyclics Drug, then the stock price of the Pharmacyclics Drug should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Pharmacyclics Drug should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What will be a multi year spillover effect of various taxation regulations.

What can impact the cash flow of the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Understanding of risks involved in the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Pharmacyclics: Financing Research & Development

References & Further Readings

Richard S. Ruback, Malcolm P. Baker, Aldo Sesia (2018), "Pharmacyclics: Financing Research & Development Harvard Business Review Case Study. Published by HBR Publications.


Sumida Corp SWOT Analysis / TOWS Matrix

Technology , Electronic Instr. & Controls


South32 Ltd SWOT Analysis / TOWS Matrix

Basic Materials , Misc. Fabricated Products


RLJ Lodging SWOT Analysis / TOWS Matrix

Services , Real Estate Operations


Hokkaido Coca Cola Bottling SWOT Analysis / TOWS Matrix

Consumer/Non-Cyclical , Beverages (Nonalcoholic)


Aves One SWOT Analysis / TOWS Matrix

Services , Rental & Leasing


Hudson's Bay Company SWOT Analysis / TOWS Matrix

Services , Retail (Department & Discount)


Agritek Holdings SWOT Analysis / TOWS Matrix

Financial , Consumer Financial Services


HRnetGroup SWOT Analysis / TOWS Matrix

Services , Business Services


Gujarat Pipavav Port SWOT Analysis / TOWS Matrix

Transportation , Misc. Transportation